Regeneron posted its Eylea updates as the company reported ... cholesterol med Praluent, suffered a 19% sales decline to $57 million in the U.S. The company also shares sales on the immunology ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron’s shares have lost 14.1% year to date compared with the industry’s decline of 4.7%. Eylea’s sales in the United States plunged 39% year over year to $736 million, primarily due to ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Regeneron anticipates a decline in EYLEA sales due to biosimilar competition. DUPIXENT continues to expand globally, with significant growth expected by 2030. The company is investing $7 billion ...

Starting in 2025, the Eylea franchise as a whole began to decline due to ... We assign Regeneron a Medium Morningstar Uncertainty Rating, as its future sales are well diversified with several ...

To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. The initial uptake of Eylea HD has been strong as Eylea patients transition to the higher dose. Sales of Eylea ...

Regeneron’s shares have lost 14.1% year to date compared with the industry’s decline of 4.7%. Image Source: Zacks Investment Research Eylea’s sales in the United States plunged 39% year over ...